NCT07097363

Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma

Recruiting now Phase 2 Last updated 15 January 2026

What this trial tests

Phase 2 trial testing Biospecimen Collection in B-Cell Non-Hodgkin Lymphoma in 18 participants. Currently enrolling.

Timeline

7 December 2025

Primary endpoint
31 May 2030

31 May 2030

Quick facts

Lead sponsor	University of Washington
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	18
Start date	7 December 2025
Primary completion	31 May 2030
Estimated completion	31 May 2030
Sites	1 location across United States

Drugs / interventions tested

• Biospecimen Collection
• Bone Marrow Aspiration
• Bone Marrow Biopsy
• Computed Tomography
• Cyclophosphamide (cyclophosphamide) — full drug profile →
• Doxorubicin
• Echocardiography Test
• Epcoritamab (EPCORITAMAB) — full drug profile →
• Etoposide
• Fludeoxyglucose F-18 (FLUDEOXYGLUCOSE) — full drug profile →
• Multigated Acquisition Scan
• Positron Emission Tomography
• Prednisone (prednisone) — full drug profile →
• Rituximab

Conditions studied

• B-Cell Non-Hodgkin Lymphoma — all drugs for B-Cell Non-Hodgkin Lymphoma →
• Burkitt Lymphoma — all drugs for Burkitt Lymphoma →
• Diffuse Large B-Cell Lymphoma, Not Otherwise Specified — all drugs for Diffuse Large B-Cell Lymphoma, Not Otherwise Specified →
• EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified — all drugs for EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified →

Sponsor

University of Washington

Who can join

18 and older, any sex, with B-Cell Non-Hodgkin Lymphoma or Burkitt Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase II trial tests the safety, best dose, and effectiveness of epcoritamab when given with etoposide, cyclophosphamide, vincristine, doxorubicin, prednisone and rituximab (EPOCH-R) for the treatment of patients with aggressive B-cell non-Hodgkin lymphoma. Epcoritamab is a bispecific antibody that can bind to two different antigens at the same time. Epcoritamab binds to CD3, a T-cell surface antigen, and CD20 (a tumor-associated antigen that is expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell cancers) and may interfere with the ability of cancer cells to grow and spread. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill cancer cells. It may also lower the body's immune response. Vincristine is in a class of medications called vinca alkaloids. It works by stopping cancer cells from growing and dividing and may kill them. Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's DNA and may kill cancer cells. It also blocks a certain enzyme needed for cell division and DNA repair. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. The EPOCH-R is administrated as the standard of care treatment. This may help the immune system kill cancer cells. Giving epcoritamab with EPOCH-R may be safe, tolerable, and effective in treating patients with aggressive B-cell non-Hodgkin lymphoma.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.